Co-Diagnostics, Inc. has announced the acquisition of an additional $1 million loan to bolster its working capital. This financial maneuver is crucial for the company as it navigates the competitive landscape of the surgical and medical instruments industry.
The loan agreement, dated November 18, 2026, was made with J.J. Astor & Co. and involves a senior secured convertible installment promissory note. This funding is part of Co-Diagnostics' broader strategy to enhance liquidity and support ongoing operational needs.
Company Background
Co-Diagnostics, Inc. operates within the surgical and medical instruments and apparatus sector, classified under SIC 3841. The company is publicly traded under the ticker CODX on the Nasdaq exchange. Established in Utah, Co-Diagnostics focuses on developing and providing innovative diagnostic solutions.
Details from the Filing
According to the recent filing (accession number 0001493152-26-053511), the additional loan was funded by J.J. Astor & Co. and comes with a senior secured convertible installment promissory note with an original principal amount of $1.35 million. The net cash proceeds to the company from this transaction amount to approximately $960,000 after accounting for a $40,000 origination fee.
The terms of the Additional Note stipulate that it requires 30 weekly installment payments of $45,000 starting November 25, 2026, with a final maturity date set for June 16, 2027. The note is secured by a senior-priority lien on substantially all assets of Co-Diagnostics and its subsidiaries.
Additionally, the company has the option to prepay the Additional Note without penalty, provided certain conditions are met. If paid in full within 45 days, the repayment amount may be reduced, reflecting a factor rate adjustment.
Impact on Stakeholders
This financial move is expected to impact various stakeholders, including investors, employees, and suppliers. For investors, the successful acquisition of this loan may signal Co-Diagnostics' commitment to maintaining operational stability and pursuing growth opportunities. Employees may benefit from enhanced job security as the company strengthens its financial position, while suppliers might see continued business as the company secures necessary funding.
What's Next?
The filing does not specify what happens next, but it indicates that the company is required to ensure a reverse stock split is effective by November 24, 2026, to avoid default under the loan terms.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










